Physician profile
Robert Eugene Arthur
NPI 1275531519
$16,418.03
in general payments reported to CMS, 2019-2025
20 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,437 · 2020: $6,432 · 2021: $3,202 · 2022: $1,677 · 2023: $1,491 · 2024: $39.59 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,016.48 | 2020 | |
| Janssen Biotech, INC. | $4,796.11 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $851.18 | 2021-2023 | Saphnelo |
| Janssen Scientific Affairs, LLC | $628.23 | 2019-2022 | |
| Horizon Therapeutics Plc | $572.95 | 2020-2023 | Krystexxa |
| Amgen INC. | $526.89 | 2019-2023 | Enbrel, Amjevita, Avsola |
| Glaxosmithkline, LLC. | $474.67 | 2019-2025 | Benlysta |
| Abbvie INC. | $405.38 | 2019-2023 | Rinvoq, Skyrizi |
| Ucb, INC. | $384.43 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $372.33 | 2019-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $238.22 | 2019-2021 | |
| Pfizer INC. | $217.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $195.27 | 2022-2023 | |
| Genentech USA, INC. | $165.44 | 2022-2023 | Actemra |
| Genzyme Corporation | $124.99 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $123.10 | 2019 | |
| Celgene Corporation | $116.28 | 2019 | |
| Aurinia Pharma U.S., INC. | $104.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.08 | 2022-2024 | Ofev |
| Organon LLC | $15.71 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.